Compare HBB & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | OBIO |
|---|---|---|
| Founded | 1904 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 240.7M |
| IPO Year | 2017 | 2020 |
| Metric | HBB | OBIO |
|---|---|---|
| Price | $22.73 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 26.2K | ★ 497.3K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $606,852,000.00 | $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | $87.42 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $12.72 | $2.20 |
| 52 Week High | $23.83 | $5.42 |
| Indicator | HBB | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 66.88 | 52.38 |
| Support Level | $17.90 | $3.96 |
| Resistance Level | N/A | $4.82 |
| Average True Range (ATR) | 1.00 | 0.27 |
| MACD | 0.30 | 0.04 |
| Stochastic Oscillator | 76.55 | 36.53 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.